A5086784431- Osteoarthritis Treatment and Mechanisms
- Systemic Sclerosis and Related Diseases
- Inflammatory mediators and NSAID effects
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Systemic Lupus Erythematosus Research
- Microbial infections and disease research
- Immune Cell Function and Interaction
- Celiac Disease Research and Management
- Cell Adhesion Molecules Research
- Cytokine Signaling Pathways and Interactions
- Reproductive System and Pregnancy
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Rheumatoid Arthritis Research and Therapies
- Pain Mechanisms and Treatments
- Renal Diseases and Glomerulopathies
- Immunotherapy and Immune Responses
- Quinazolinone synthesis and applications
- Sesquiterpenes and Asteraceae Studies
- Pharmacology and Obesity Treatment
- Dermatologic Treatments and Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Helicobacter pylori-related gastroenterology studies
- Medicinal plant effects and applications
- Immune Response and Inflammation
University of Utah
2011-2022
Center for Rheumatology
1999-2018
Oklahoma Medical Research Foundation
2015
University of Oklahoma Health Sciences Center
2015
Hospital for Special Surgery
2015
Intermountain Healthcare
2015
Cornell University
2015
Johns Hopkins University
2015
University of Illinois Chicago
2015
University of Toronto
2015
Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy safety as a treatment for knee pain from osteoarthritis.We randomly assigned 1583 patients with symptomatic osteoarthritis receive 1500 mg of glucosamine daily, 1200 both sulfate, 200 celecoxib or placebo 24 weeks. Up 4000 acetaminophen daily was allowed rescue analgesia....
Background: Because systemic lupus erythematosus (SLE) affects women of reproductive age, pregnancy is a major concern. Objective: To identify predictors adverse outcomes (APOs) in patients with inactive or stable active SLE. Design: Prospective cohort. Setting: Multicenter. Patients: 385 (49% non-Hispanic white; 31% prior nephritis) SLE the PROMISSE (Predictors Pregnancy Outcome: Biomarkers Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study. Exclusion criteria were...
<h3>Objectives</h3> To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis severe pain. <h3>Methods</h3> Double-blind Multicentre Osteoarthritis interVEntion trial SYSADOA (MOVES) conducted France, Germany, Poland Spain evaluating treatment CS+GH 606 Kellgren Lawrence grades 2–3 moderate-to-severe pain (Western Ontario McMaster index (WOMAC) score ≥301; 0–500 scale). Patients were randomised to...
Abstract Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able slow structural damage remain elusive. This study was undertaken evaluate effect glucosamine chondroitin sulfate (CS), alone or in combination, as well celecoxib placebo on progressive loss joint space width (JSW) patients with OA. Methods A 24‐month, double‐blind, placebo‐controlled study, conducted at 9 sites United States part...
Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies medical treatment OA are limited.
Objective Studies in mouse models implicate complement activation as a causative factor adverse pregnancy outcomes (APOs). We investigated whether of early predicts APOs women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. Methods The PROMISSE Study enrolled pregnant SLE aPL antibodies (n=487) and healthy controls (n=204) at <12 weeks gestation evaluated them monthly. were: fetal/neonatal death, preterm delivery <36 because placental insufficiency or...
Background and objectives Kidney disease is a critical concern in counseling patients with lupus considering pregnancy. This study sought to assess the risk of renal flares during pregnancy women previous nephritis partial or complete remission, particularly those antidouble-stranded DNA antibodies low complement levels, new-onset stable/mildly active SLE. Design, setting, participants, & measurements We assessed (renal de novo kidney disease) associated predictors urine protein ≤1000 mg...
Systemic lupus erythematosus carries an increased risk of pregnancy complications, including preeclampsia and fetal adverse outcomes. To identify the underlying molecular mechanisms, we longitudinally profiled blood transcriptome 92 patients 43 healthy women during postpartum performed multicolor flow cytometry in a subset them. We also 25 undergoing assisted reproductive technology to monitor transcriptional changes around embryo implantation. Sustained down-regulation multiple immune...
Abstract Background Lupus patients are at risk for pregnancy loss, and it has been generally accepted that women with SLE should have low disease activity prior to conception. However, there conflicting results regarding the effect of on flares. This study aims identify predictors flares during after in inactive or stable first trimester characterize estimate frequency post-partum these patients. Methods multicenter, prospective PROMISSE (Predictors Pregnancy Outcome: Biomarkers...
Objective. To explore the relationship between fatigue and work productivity loss (WPL) in people with psoriatic arthritis (PsA). Methods. Data were collected from participants Utah Psoriasis Initiative Arthritis registry January 2010 May 2013. WPL was measured 8-item Work Limitations Questionnaire. Fatigue assessed question 1 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI#1), “How would you describe overall level of fatigue/tiredness have experienced?” Psoriatic Quality Life...
Abstract This report describes 2 patients with longstanding seropositive rheumatoid arthritis (RA) treated oral methotrexate (MTX) who developed large cell lymphoma of B phenotype. In situ hybridization studies showed nuclear staining for Epstein‐Barr virus (EBV) within the malignant lymphoid cells. both cases, was undetectable several weeks after diagnostic biopsy followed by discontinuation MTX. These observations suggest that, in RA develop an EBV‐associated lymphoproliferative disorder,...
The purpose of this study was to analyze antinuclear antibody (ANA) screening by enzyme-linked immunosorbent assay (ELISA) followed indirect fluorescent (IFA) testing confirm and characterize the pattern titer antibody. We evaluated 4 ANA ELISAs 1 HEp-2 IFA substrate in 224 clinically defined serum samples consisting 30 from systemic lupus erythematosus (SLE) cases, 94 rheumatoid arthritis 100 healthy donors plus 495 submitted for routine 12 reference distributed Centers Disease Control...
To identify novel non-major histocompatibility complex (non-MHC) genetic loci controlling the severity of homologous rat type II collagen-induced arthritis (CIA).We conducted a genome-wide scan to CIA regulatory quantitative trait (QTL) in an F2 cross between DA (CIA highly susceptible) and ACI resistant) inbred rats immunized with collagen (RII). These strains share MHC/RT1av1 haplotype required for susceptibility RII-induced CIA.F2 females had higher median scores than did males. Relative...
Abstract Objective To investigate the familiality of systemic sclerosis (SSc) in relation to Raynaud's phenomenon (RP) (a marker vasculopathy), other autoimmune inflammatory disease, and fibrotic interstitial lung disease (ILD). Methods A genealogic resource, Utah Population Database (UPDB), was used test heritability RP, ILD. Diseases were defined by International Classification Diseases, Ninth Revision codes identified from statewide discharge data, University Health Science Center...
Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy skin, lung, gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, quality life (QOL) other GIT diseases have been successful. In case series we report three patients that had significant improvement total symptoms as measured by the 10-point faces scale...
Mycoplasma arthritidis, an agent of chronic proliferative arthritis rodents, secretes a potent soluble superantigen, MAM, that is active for both murine and human T B lymphocytes. We now report the complete nucleotide amino acid sequence MAM show it to be distinct from other proteins not closely related phylogenetically superantigens. Two functional domains on are identified based ability peptides encompassing these regions inhibit lymphocyte proliferation by intact molecule. One shares...
Objective. The main histopathological focus of systemic sclerosis (SSc) has concentrated on fibrotic changes. We investigated the microvasculature alterations in skin patients with SSc at various stages disease duration whole-field digital microscopy. Methods. Twenty consecutive SSc, 1 Raynaud’s phenomenon (RP) without and 4 healthy controls underwent punch biopsy medial forearm. Eighteen were included primary analysis. Two recent-onset diffuse cutaneous disease, repeat biopsy, patient RP...
Osteoarthritis (OA) is a common debilitating disease characterized by abnormal remodeling of the cartilage and bone articular joint. Ameliorating therapeutics are lacking due to limited understanding molecular pathways affecting initiation progression. Notably, although link between inflammation overt OA well established, role as driver occurrence highly disputed. We analyzed family with dominant inheritance early-onset found that affected individuals harbored rare variant allele encoding...
Mycoplasma arthritidis, an agent of rodent arthritis, produces a potent superantigen (SAg), MAM. Previous work established that MAM is presented to T cells by murine H-2E or the homologous human HLA-DR molecules and lymphocytes lacking functional molecule fail respond Recently, more purified preparations known protein content have become available. This enabled us effectively compare response with other SAgs using from mice whose express different H-2A HLA-DQ molecules. Here we demonstrate...
The catastrophic antiphospholipid antibody syndrome (CAPS) is an uncommon disorder characterized by widespread micro- and macrovascular changes due to intravascular thrombosis. This complication of the often fatal recurrences are very rare. differential diagnosis CAPS includes thrombotic thrombocytopenic purpura (TTP) this distinction may be difficult, but essential, for appropriate therapy. Plasmapheresis effective in both conditions, anticoagulation, a mainstay treatment CAPS, could...